|
May 1, 2008
ABBOTT, TAKEDA CONCLUDE TAP JOINT VENTURE
March 26, 2008
SHIRE AND TAP AGREE TO CO-PROMOTE LIALDATM (MESALAMINE), THE FIRST ORAL ONCE-DAILY MESALAMINE FOR PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
March 19, 2008
TAKEDA, ABBOTT ANNOUNCE PLANS TO CONCLUDE TAP JOINT VENTURE
January 3, 2008
TAP PHARMACEUTICAL PRODUCTS INC. FILES NEW DRUG APPLICATION FOR TAK-390MR IN PATIENTS WITH ACID-RELATED DISORDERS
| 
